PUBLISHER: Grand View Research | PRODUCT CODE: 1771706
PUBLISHER: Grand View Research | PRODUCT CODE: 1771706
Surgical Gowns Level AAMI 3 Market Summary
The global surgical gowns level AAMI 3 market size was estimated at USD 756.52 million in 2024 and is projected to reach USD 1,985.77 million by 2033, growing at a CAGR of 11.27% from 2025 to 2033. This growth is attributed to the rising surgical procedure volumes, the increasing prevalence of healthcare-associated infections, and stringent global infection prevention and control standards.
The aging global population further supports the market expansion, the growing demand for moderate barrier protection gowns in inpatient and outpatient settings, and heightened awareness of surgical safety, particularly post-pandemic. In addition, innovation in gown materials and healthcare infrastructure improvements in emerging economies are anticipated to boost market adoption further over the forecast period. According to a study by the CDC, approximately 1 in every 31 hospitalized patients in the U.S. acquires a healthcare-associated infection, translating to an estimated 633,300 cases annually. In 2023, the Pennsylvania Patient Safety Reporting System recorded 23,970 HAI incidents reported by long-term care facilities across the state, highlighting the ongoing challenge of infection control in acute and extended care settings.
The rising incidence of healthcare-associated infections, including Surgical Site Infections (SSIs), Methicillin-Resistant Staphylococcus aureus (MRSA), Clostridium difficile infections, and Central Line-Associated Bloodstream Infections (CLABSIs), is a significant factor fueling the demand for AAMI Level 3 surgical gowns. These infections compromise patient safety, leading to longer hospital stays, increased morbidity, and higher healthcare costs. Among these, CLABSIs are particularly concerning in surgical and intensive care settings, where patients require invasive devices like central venous catheters. Proper use of personal protective equipment, including surgical gowns with moderate barrier protection, is critical in reducing contamination risk during line insertions and surgical procedures. In response to these risks, healthcare institutions are adopting more stringent infection prevention and control protocols supported by CDC, WHO, and ECDC recommendations. AAMI Level 3 gowns, known for their balance of comfort and fluid resistance, are increasingly used in settings with moderate exposure to blood and bodily fluids, including operating rooms and intensive care units. The global focus on reducing HAIs, especially in light of rising antimicrobial resistance, continues to drive strong demand for high-standard protective apparel, boosting the market. According to the Australian Institute of Health and Welfare, 2023-2024, 1,699 SABSI cases were reported across public hospitals, occurring over 22.7 million patient care days, equating to a national rate of 0.75 cases per 10,000 patient days.
The data below highlights the top 15 U.S. states most affected by Central Line-Associated Bloodstream Infections (CLABSIs) in 2022. These high-capacity healthcare hubs perform a significant volume of invasive procedures involving central lines, increasing the risk of bloodstream infections. As a result, hospitals in these states are under greater pressure to implement rigorous infection prevention protocols, including the mandatory use of AAMI Level 3 surgical gowns that offer essential fluid and microbial barrier protection during central line insertions and maintenance.
Global Surgical Gowns Level AAMI 3 Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global surgical gowns level AAMI 3 market report on the basis of gown type, surgery, end use, usability, and region: